Recent Finacing
Recent Raise
Mebias Discovery develops pathway-selective GPCR drugs using native GPCR purification and 19F-protein NMR, advancing motilin, S1P1, and mu-opioid programs for gastrointestinal, pain, and neuroinflammation indications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Mebias Discovery.
